Telmisartan in elderly – the facts speak for themselves Review article
Article Sidebar
Published:
Sep 30, 2019
Keywords:
hypertension in the elderly, telmisartan, amlodipine, fixed therapy
Main Article Content
Abstract
The worldwide increase in the elderly population is associated with concurrent increases in prevalence of systemic hypertension and morbidity and mortality from vascular complications of hypertensive disease. The elderly population with hypertension is at especially high risk for vascular complications. Telmisartan is highly effective antihypertensive agent and is widely regarded as having tolerability profile similar to that of placebo. The combination therapy with telmisartan plus amlodipine may exert beneficial cardiometabolic effect in elderly patients.
Article Details
How to Cite
Kostka-Jeziorny , K., & Tykarski , A. (2019). Telmisartan in elderly – the facts speak for themselves. Medycyna Faktow (J EBM), 11(3(40), 185-188. https://doi.org/10.24292/01.MF.0318.3
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce 2015; 1: 1-70.
2. Benson S.C., Pershadsingh H.A., Ho C.I. et al.: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma- modulating activity. Hypertension 2004; 43(5): 993-1002.
3. Burnier M., Brunner H.R.: Angiotensin II receptor antagonists. Lancet 2000; 355: 637-645.
4. Schmieder R.E., Delles C., Mimran A. et al.: Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 2007; 30: 1351-1356.
5. Laurent S., Cockcroft J., Van Bortel L. et al.: Expert consensus document on arterial stiffness: methodological aspects and clinical applications. Eur. Heart J. 2006; 27: 2588-2605.
6. Petrovic J., Petrovic D., Vukovic N. et al.: Ventricular and vascular remodeling – effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients. J. Int. Med. Res. 2005; 33(supl. 1): 39-49.
7. Neutel J.M.: Ambulatory blood pressure monitoring to assess the comparative efficacy and duration of action of a novel new angiotensin II receptor blocker – telmisartan. Blood Press. 2001; 10(supl. 4): 27-32.
8. Galzerano D., Caselli S., Breglio R. et al.: A multicentre, randomized study comparing efficacy of telmisartan versus carvedilol in preventing atrial fibrillation recurrence in hypertensive patients. Circulation 2007; 116: 556-557.
9. Barnett A.H., Bain S.C., Bouter P. et al.; Diabetic Exposed to Telmisartan and Enalapril Study Group: Angiotensin – receptor blockade versus converting – enzyme inhibition in type 2 diabetes and nephropathy. N. Engl. J. Med. 2004; 351: 1952-1961.
10. Schmieder R.E., Delles C., Mimran A. et al.: Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 2007; 30: 1351-1356.
11. Galle J., Schwedhelm E., Pinnetti S.: Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol. Dial. Transplant. 2008; 23: 3174-3183.
12. Bakris G., Burgess E., Weir M. et al.; AMADEO Study Investigators: Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 2008; 74: 364-369.
13. Makino H., Haneda M., Babazono T., Moriva T.: Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study. Hypertens. Res. 2008; 31(4): 657-664.
14. Williams B., Mancia G.: Prezentacja podczas kongresu ESH w Barcelonie 9 czerwca 2018 r. J. Hypertens. 2018 [in press].
2. Benson S.C., Pershadsingh H.A., Ho C.I. et al.: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma- modulating activity. Hypertension 2004; 43(5): 993-1002.
3. Burnier M., Brunner H.R.: Angiotensin II receptor antagonists. Lancet 2000; 355: 637-645.
4. Schmieder R.E., Delles C., Mimran A. et al.: Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 2007; 30: 1351-1356.
5. Laurent S., Cockcroft J., Van Bortel L. et al.: Expert consensus document on arterial stiffness: methodological aspects and clinical applications. Eur. Heart J. 2006; 27: 2588-2605.
6. Petrovic J., Petrovic D., Vukovic N. et al.: Ventricular and vascular remodeling – effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients. J. Int. Med. Res. 2005; 33(supl. 1): 39-49.
7. Neutel J.M.: Ambulatory blood pressure monitoring to assess the comparative efficacy and duration of action of a novel new angiotensin II receptor blocker – telmisartan. Blood Press. 2001; 10(supl. 4): 27-32.
8. Galzerano D., Caselli S., Breglio R. et al.: A multicentre, randomized study comparing efficacy of telmisartan versus carvedilol in preventing atrial fibrillation recurrence in hypertensive patients. Circulation 2007; 116: 556-557.
9. Barnett A.H., Bain S.C., Bouter P. et al.; Diabetic Exposed to Telmisartan and Enalapril Study Group: Angiotensin – receptor blockade versus converting – enzyme inhibition in type 2 diabetes and nephropathy. N. Engl. J. Med. 2004; 351: 1952-1961.
10. Schmieder R.E., Delles C., Mimran A. et al.: Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 2007; 30: 1351-1356.
11. Galle J., Schwedhelm E., Pinnetti S.: Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol. Dial. Transplant. 2008; 23: 3174-3183.
12. Bakris G., Burgess E., Weir M. et al.; AMADEO Study Investigators: Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 2008; 74: 364-369.
13. Makino H., Haneda M., Babazono T., Moriva T.: Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study. Hypertens. Res. 2008; 31(4): 657-664.
14. Williams B., Mancia G.: Prezentacja podczas kongresu ESH w Barcelonie 9 czerwca 2018 r. J. Hypertens. 2018 [in press].